Synthesis, biodistribution and effects of farnesyltransferase inhibitor therapy on tumour uptake in mice of 99mTc labelled epidermal growth factor.

Journal article

OBJECTIVE: The goal of this study was to develop a 99mTc labelled human epidermal growth factor (hEGF) for the in-vivo prediction of cancer cell response to farnesyltransferase inhibitor (FTI) therapy. This is based on the observation that internalization of EGF receptors is inhibited by FTIs. METHODS: We describe the radiolabelling of 99mTc-hEGF using the hydrazinonicotinamide (HYNIC) linker. Binding characteristics of 99mTc-HYNIC-hEGF to the EGF receptor are explored using an in-vitro bind...

Expand abstract

Authors: Cornelissen, B; Kersemans, V; Burvenich, I; Oltenfreiter, R; Vanderheyden, J

• Publication status: Published
• Journal: Nuclear medicine communications
• Volume: 26
• Issue: 2
• Pages: 147-153
• Publication date: 2005-02-01
• DOI: 10.1097/00006231-200502000-00012
• EISSN: 1473-5628
• ISSN: 0143-3636
• Language: English
• Keywords: Organ Specificity; Quinolones; Treatment Outcome; Animals; Farnesyltranstransferase; Cell Line, Tumor; Tumor Markers, Biological; Metabolic Clearance Rate; Mice; Receptor, Epidermal Growth Factor; Organotechnetium Compounds; Radiopharmaceuticals; Epidermal Growth Factor; Humans; Tissue Distribution; Colonic Neoplasms; Male; Alkyl and Aryl Transferases